Patient Information Leaflets (PILs)
These Patient Information Leaflets (PILs) are specially written by the British Association of Dermatologists (BAD).
The BAD has been awarded The Information Standard certification for the process it employs to develop information products aimed at the general public, which include PILs, Sun Awareness Campaign materials, and other information products.
The BAD shall hold responsibility for the accuracy of the information published, and neither the scheme operator nor the scheme owner shall have any responsibility for costs, losses, or direct or indirect damages or costs arising from inaccuracy of information or omissions in information published on the website on behalf of the BAD.
There are thousands of different skin complaints, therefore, the focus of the British Association of Dermatologists' PILs production is on the most common, rarest or debilitating skin conditions.
The offer to provide details of source materials used to inform the British Association of Dermatologists' PILs is for instances where the advice provided in the PILs does not reflect local practice and therefore evidence supporting said advice needs to be produced. It is not an offer to conduct literature searches or supply bibilographic materials for your own research.
For the latest BAD advice on Covid-19 for patients, please check the News and Media section of the website. Find this here. Our information for healthcare professionals is here.
Etanercept is one of the first of a group of modern drugs called ‘biologics’ or ‘biologicals.’ Unlike ordinary drugs which can usually be made from chemicals in a test tube, biologics are complex molecules made by living cells. They are designed to mimic or change processes in the human body and are used to treat a range of diseases from cancer to arthritis.
Etanercept blocks the effect of tumor necrosis factor alpha (TNF-alpha) so it is called an ‘anti-TNF’ drug. TNF-alpha helps the body fight infection and cancer, but when over produced it can have harmful effects. Over-production of TNF occurs in several diseases including Crohn’s disease, psoriasis and inflammatory arthritis, so anti-TNF drugs have been as treatment.